<DOC>
	<DOCNO>NCT00004075</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin treating patient solid tumor remove surgery .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Solid Tumors That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) , administer 2 different dose schedule , patient unresectable solid tumor . - Determine pharmacokinetics drug patient . - Assess effect drug heat shock protein chaperone complex component client proteins lymphoma tissue obtain pre- post-treatment patient relapse lymphoma . - Determine response drug patient . OUTLINE : This dose-escalation study . Patients assign 1 2 treatment group . - Group I : Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Group II : Patients receive 17-AAG IV 1 hour day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 1-6 solid tumor patient receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 patient either lymphoma superficial solid tumor accessible biopsy treat group II MTD . Patients follow 3 month . PROJECTED ACCRUAL : A total 58-130 patient ( 30-72 group I 28-58 group II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically cytologically confirm solid tumor* Unresectable disease Hodgkin 's nonHodgkin 's lymphoma Relapsed disease Failed least 1 prior therapy Neoplastic cell accessible biopsy NOTE : *Only patient biopsyaccessible superficial tumor lymphoma eligible maximum tolerate dose determined No known standard therapy potentially curative definitely capable extend life expectancy exist No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST great 2.5 time ULN Alkaline phosphatase great 2 time ULN ( 5 time ULN liver involvement ) Renal : Creatinine great 1.25 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No uncontrolled infection No seizure disorder No history serious allergic reaction egg PRIOR CONCURRENT THERAPY : Biologic therapy : More 4 week since prior immunotherapy More 4 week since prior biologic therapy No concurrent immunotherapy No concurrent routine prophylactic use colonystimulating factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy : More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover acute reversible toxic effect No concurrent chemotherapy Endocrine therapy : No concurrent birth control pills No concurrent steroid antiemetic Radiotherapy : More 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No prior radiopharmaceutical No concurrent radiotherapy Surgery : Not specify Other : No concurrent 3A4 enzyme inhibitor ( e.g. , verapamil , erythromycin , miconazole , ketoconazole ) No concurrent investigational ancillary therapy No concurrent enrollment another study involve pharmacologic agent ( e.g. , drug , biologics , immunotherapy approach , gene therapy ) symptom control therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>